Maybe if BL1040 received EMA approval, (forgetting that its CE Registration trial failed) and BL8040 just announced that the expansion phase of the AML Phase 2a trial boasted a 55% response rate, then MAYBE.
But as of right now, you are lucky that the share price isn't .70
roth is worse than our CEO
I didn't see BLRX going any lower than the $1.20 -$1.25 range and as such I loaded up. Hind sight always 20/20, maybe I should have waited. lol
Right now the only hope for the near term I can see realistically is that the response rate increases to the 50-55% range when they announce the data from the expansion phase of the 2A trial for AML due sometime in March, if the trial hasn't been again delayed.
If the response rate is less than 38%, say goodbye to BL8040 for AML and hello to A .40 stock
Off the BL8040 topic, can someone please tell me why they are not taking back BL1040 from BLPH? The trial was terribly managed to say the least. It could just be another badly written licensing agreement.
CEO is horrible and needs to go before we are trading in the pink sheets.
No successful candidate to date to bring in any revenue
Novartis paid $10 mil and will want their money back with interest before they even think of entertaining the idea of selecting a candidate for a clinical trial.
Merck didn't even have to cough up a dime to get BLRX to foot the b ill for a clinical trial that will help Merck's candidate.
BL1040, A possible billion dollar a year candidate held in limbo, BLPH calling the shots
CSO was been replaced with an advisory board, both the CSO & CEO are so bad at trial oversight and selection of licensing partners that big investors demanded that they seek an oversight board
BL8040 is the only game, BLRX has been reduced to a one pony show.
Bottom line is that even if BL8040 works like a charm and increases stem cell mobilization, if the combination of BL8040 and the other drugs does not increase overall survival, then you have another failed trial
Why didn't they base the clinical trial with BL8040 and the 4-5 different and successful standard of care treatments for AML? Instead they try an end run and remove one the the combined chem drugs and replace with BL8040. Very bad and costly decision as they discover that BL8040 is not work as well as t he current standard of care.
Biggest lie, is that they don't need cash now or that they are flush until 2018. 2018 if they run the only 2 trials that have underway presently.
They will need a ton of cash to run a whole new trial to incorporate 8040 into the current standard of care. CEO got herself in a big jam and it all started when the 1040 trial failed due to a lack of professional oversight.
It's coming, no wonder Teva gave these clowns the boot!
ALI NEEDS TO GO!!!!!!!!!!!
Very good point Auz, 6-8 hours could be lost if a stroke occurred during a normal night of sleep. H saw the mistakes Chugai took as failure. Not uncommon with large pharms stepping into new areas of biotech that is unfamiliar.
I still believe that one person can make a difference
We have potential blockbuster drugs with BL1040 and BL8040, both trial have been horribly mismanaged thus the reason why the CSO was fired and an advisory put in place.
All to take the heat off the CEO, who has been inept at best in her contribution to overseeing the clinical trials . At least she did finally recognize her limitations.
I'll be the first to admit that I have made some rather large purchases at $1.25 & $1.21 thinking we were going to rocket up once they start hyping the stock, then the add on offering............
I can't believe that major investors are not demanding for the CEO to step down unless they are actively searching for her replacement and want that position secured before she is replaced.
Delays for all trials including BL8040, all candidates making it to phase 3 trials have failed, what is going on with BL1040? CEO granted BLPH an extension for payment which BLRX probably never received due to the failed trial? BL1040, a billion dollar a year potential winner sitting in limbo with BLPH doing nothing and BLRX helpless to do anything?
Nothing in the pipeline presently that will generate a major source of income? Nothing from Novartis
This is pitiful, get rid of this CEO before she bankrupts this company!
One word can summarize your question..........gilly
Can you start the countdown to the hemorrhoid trial. I believe this would help encourage investors to pony up now.
Ramping up towards the IND for the hemorrhoid trial. Athersyss has already signed up hoping for relief in his butt and stock account
Yes - BLRX will be huge late February early March 2016
Novartis & Merck on board
BL 1040 trial killed them otherwise BLRX would have been a $5-6 stock conservatively.
That is how gilly thought up the trial, we certainly know he doesn't have a green thumb. Maybe in a couple of years we could hot the $1.50 - $2.00 zone?